Reference health
Adverse side‐effects to biological agents
39/39 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
7 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 39 checked references that resolve
resolves10.1038/256495a0
Continuous cultures of fused cells secreting antibody of predefined specificity
resolves10.1016/S0896-8411(89)80003-4
Anti-CD4 antibody treatment of patients with rheumatoid arthritis: II. Effect of in vivo treatment on in vitro proliferative response of CD4 cells
resolves10.1016/j.jaci.2005.03.028
Adverse reactions to biologic agents: Focus on autoimmune disease therapies
resolves10.1200/JCO.2005.00.6916
Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?
resolves10.1093/ndt/gfh1072
Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery
resolves10.1056/NEJMoa020888
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
resolves10.1056/NEJM200011303432202
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
resolves10.1056/NEJM199209033271018
Anaphylactic Shock after Retreatment with OKT3 Monoclonal Antibody
resolves10.1159/000081276
Severe Autoimmune Thrombocytopenic Purpura during Interferon-α Therapy for Chronic Myelogenous Leukemia
resolves10.1172/JCI13362
TNF and receptors in organ-specific autoimmune disease: multi-layered functioning mirrored in animal models
resolves10.1016/S0016-5085(03)00701-7
Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn’s disease: a prospective cohort study
resolves10.1016/S1074-7613(04)00108-6
Autoimmunity through Cytokine-Induced Dendritic Cell Activation
resolves10.1002/art.11137
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active‐surveillance report
resolves10.1073/pnas.1533209100
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
resolves10.1111/j.0736-8046.2004.21512.x
Concomitant Vitiligo and Psoriasis in a Patient Treated with Interferon Alfa‐2a for Chronic Hepatitis B Infection
resolves10.1007/s10067-004-1024-2
Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C
resolves10.1016/j.jocn.2003.04.009
Guillain-Barré syndrome during treatment with interferon α for hepatitis B
resolves10.1111/j.1478-3231.2005.01089.x
Long‐term outcome of interferon‐α‐induced autoimmune thyroid disorders in chronic hepatitis C
resolves10.1111/j.0105-2896.2005.00239.x
Toll‐like receptors, endogenous ligands, and systemic autoimmune disease
resolves10.1097/00000441-200409000-00008
Interferon-Alpha-Associated Sarcoidosis Responsive to Infliximab Therapy
resolves10.1159/000080523
T Regulatory Cells in Allergy and Health: A Question of Allergen Specificity and Balance
resolves10.1615/CritRevImmunol.v25.i2.20
Platelet Activation and the CD40/CD40 Ligand Pathway: Mechanisms and Implications for Human Disease
resolves10.7326/0003-4819-138-10-200305200-00008
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
resolves10.1007/s00535-004-1452-4
Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C
resolves10.1592/phco.24.16.1546.50947
Follow‐up of Adverse Drug Reactions from Peginterferon alfa‐2b—Ribavirin Therapy
resolves10.4161/cbt.4.8.1893
Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy
The 7 references without a DOI — listed, not checked
no DOI — not checkedCellular and molecular immunology
no DOI — not checkedEpidemiology of allergic drug reactions
no DOI — not checkedClinical aspects of immunology
no DOI — not checkedOKT3‐induced cytokine‐release syndrome: occurrence beyond the second dose and association with rejection severity
no DOI — not checkedEtanercept‐induced injection site reactions: mechanistic insights from clinical findings and immunohistochemistry
no DOI — not checkedSystemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis
no DOI — not checkedCounter‐regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1111/j.1398-9995.2006.01058.x"><img src="https://citestamp.com/citestamped/10.1111/j.1398-9995.2006.01058.x/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1111/j.1398-9995.2006.01058.x)